Company / SG&A Expense
Elicio Therapeutics, Inc. SG&A Expense History
FY2021-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$18.5M
FY2022
5-year range
$18.0M / $18.5M
FY2021-FY2022
Trend
+2.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$18M in FY2022.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, sg&a expense increased 2.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.36 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $18.5M | +2.8% |
| FY2021 | $18.0M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026